New phosphate binder for kidney disease patients

摘要

PATENTS with chronic kidney disease (CKD) stage V now have another choice of phosphate binding medicine for the management of their hyperphosphataemia. Colestilan is available in granule and tablet form, and is indicated for the treatment of hyperphosphataemia in adults with CKD stage V who are receiving haemodiafysis or peritoneal dialysis. Colestilan is marketed as BindRen by Mitsubishi Pharma Europe, which said: "BindRen is the first granule formulation, non-absorbed, metal and calcium-free phosphate binder [and] does not require mixing or preparation.